JP2021506814A - 安定化ペプチドによって介在される標的タンパク質の分解 - Google Patents
安定化ペプチドによって介在される標的タンパク質の分解 Download PDFInfo
- Publication number
- JP2021506814A JP2021506814A JP2020532803A JP2020532803A JP2021506814A JP 2021506814 A JP2021506814 A JP 2021506814A JP 2020532803 A JP2020532803 A JP 2020532803A JP 2020532803 A JP2020532803 A JP 2020532803A JP 2021506814 A JP2021506814 A JP 2021506814A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- protein
- amino acid
- seq
- staple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VZRVSGYPBXOIIR-ZENAZSQFSA-N CCN[C@@H](CCCCNC(COc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O)=O)C(N=C(C)C)=O Chemical compound CCN[C@@H](CCCCNC(COc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O)=O)C(N=C(C)C)=O VZRVSGYPBXOIIR-ZENAZSQFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096835A JP2023107892A (ja) | 2017-12-15 | 2023-06-13 | 安定化ペプチドによって介在される標的タンパク質の分解 |
| JP2025117357A JP2025137626A (ja) | 2017-12-15 | 2025-07-11 | 安定化ペプチドによって介在される標的タンパク質の分解 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599608P | 2017-12-15 | 2017-12-15 | |
| US62/599,608 | 2017-12-15 | ||
| PCT/US2018/065784 WO2019118893A1 (en) | 2017-12-15 | 2018-12-14 | Stabilized peptide-mediated targeted protein degradation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096835A Division JP2023107892A (ja) | 2017-12-15 | 2023-06-13 | 安定化ペプチドによって介在される標的タンパク質の分解 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506814A true JP2021506814A (ja) | 2021-02-22 |
| JP2021506814A5 JP2021506814A5 (cg-RX-API-DMAC10.html) | 2022-01-18 |
Family
ID=65201672
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532803A Pending JP2021506814A (ja) | 2017-12-15 | 2018-12-14 | 安定化ペプチドによって介在される標的タンパク質の分解 |
| JP2023096835A Pending JP2023107892A (ja) | 2017-12-15 | 2023-06-13 | 安定化ペプチドによって介在される標的タンパク質の分解 |
| JP2025117357A Pending JP2025137626A (ja) | 2017-12-15 | 2025-07-11 | 安定化ペプチドによって介在される標的タンパク質の分解 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096835A Pending JP2023107892A (ja) | 2017-12-15 | 2023-06-13 | 安定化ペプチドによって介在される標的タンパク質の分解 |
| JP2025117357A Pending JP2025137626A (ja) | 2017-12-15 | 2025-07-11 | 安定化ペプチドによって介在される標的タンパク質の分解 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200354413A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3724216A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2021506814A (cg-RX-API-DMAC10.html) |
| CN (2) | CN120118207A (cg-RX-API-DMAC10.html) |
| AU (3) | AU2018385697B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3078682A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019118893A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025137626A (ja) * | 2017-12-15 | 2025-09-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化ペプチドによって介在される標的タンパク質の分解 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| CN111393519B (zh) * | 2019-11-21 | 2022-11-08 | 中国药科大学 | 作为krasg12c/sos1抑制剂的新型订书肽及其用途 |
| WO2021141662A1 (en) * | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| AU2021262752A1 (en) * | 2020-04-27 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and HDMX-selective p53 peptides and uses thereof |
| US20220025341A1 (en) * | 2020-05-29 | 2022-01-27 | Massachusetts Institute Of Technology | Minimal peptide fusions for targeted intracellular protein degradation |
| AR122707A1 (es) * | 2020-06-23 | 2022-09-28 | Genentech Inc | Compuestos macrocíclicos y métodos de uso de los mismos |
| WO2022047734A1 (zh) * | 2020-09-04 | 2022-03-10 | 孔二艳 | 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用 |
| WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| GB202018608D0 (en) * | 2020-11-26 | 2021-01-13 | Zentraza Ltd | Adhesive peptides |
| WO2022129621A1 (en) * | 2020-12-18 | 2022-06-23 | John Innes Centre | Methods for targeted protein degradation |
| WO2022194087A1 (en) * | 2021-03-16 | 2022-09-22 | Cullgen (Shanghai) , Inc. | Modified proteins and protein binders |
| CN113845598B (zh) * | 2021-09-18 | 2023-06-30 | 中国人民解放军海军军医大学 | 一种蛋白质靶向嵌合体降解mdm2/mdmx蛋白的订书肽缀合物及其用途 |
| US20230257725A1 (en) * | 2021-10-22 | 2023-08-17 | Massachusetts Institute Of Technology | Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3 |
| EP4476268A4 (en) * | 2022-02-07 | 2026-04-15 | Ubiquitx | BETA-CATENIN PROTEIN DEGRADATION |
| WO2023203127A1 (en) | 2022-04-20 | 2023-10-26 | Vib Vzw | Alphabody-based degrader molecules |
| WO2023225625A2 (en) * | 2022-05-19 | 2023-11-23 | The Scripps Research Institute | Bifunctional degraders comprising electrophilic protacs that engage dcaf1 and pharmaceutical compositions comprising the same |
| WO2024130217A1 (en) * | 2022-12-15 | 2024-06-20 | Fog Pharmaceuticals, Inc. | Stapled peptides and methods thereof |
| CN121443627A (zh) * | 2023-05-05 | 2026-01-30 | 森迪生物科学公司 | 经修饰的降解决定子多肽和其用途 |
| TW202530189A (zh) | 2023-09-29 | 2025-08-01 | 日商第一三共股份有限公司 | 3-苯基丙基胺衍生物 |
| CN117904060B (zh) * | 2023-12-21 | 2024-09-24 | 上海大学 | 一种基于parkin的靶向蛋白泛素化降解剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017201449A1 (en) * | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| EP0958305B1 (en) | 1996-07-05 | 2008-06-04 | Cancer Research Technology Limited | Inhibitions of the interaction between p53 and mdm2 |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| ES2211033T3 (es) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos. |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| BR0001870B1 (pt) | 2000-05-29 | 2014-02-25 | Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas | |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| CN109627287A (zh) | 2007-02-23 | 2019-04-16 | 爱勒让治疗公司 | 三唑大环系统 |
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| EP2208061B1 (en) | 2007-09-26 | 2017-11-08 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| GB0804701D0 (en) | 2008-03-13 | 2008-04-16 | Amura Therapeutics Ltd | Compounds |
| JP2011522796A (ja) | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター, インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | LIGURE COMBINED POLYPEPTIDES |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| US8524653B2 (en) | 2008-09-22 | 2013-09-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2010060112A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| EP2376100B1 (en) | 2009-01-14 | 2017-10-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP3698811A1 (en) | 2009-06-18 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| WO2011008260A2 (en) * | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US9227995B2 (en) | 2010-04-23 | 2016-01-05 | Øyvind Jacobsen | Peptides |
| US9297017B2 (en) | 2010-06-08 | 2016-03-29 | University Of Washington | Methods and compositions for targeted protein degradation |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| AU2011274474B2 (en) | 2010-07-09 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| EP2637680B1 (en) | 2010-11-12 | 2017-03-01 | Dana-Farber Cancer Institute, Inc. | Cancer therapies |
| EP2649099A4 (en) | 2010-12-07 | 2016-10-19 | Univ Yale | SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS |
| US8762795B2 (en) | 2010-12-17 | 2014-06-24 | Microsoft Corporation | Alerting recipients to errors occurring when accessing external services |
| SG10201601840RA (en) | 2011-09-09 | 2016-04-28 | Agency Science Tech & Res | P53 activating peptides |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| US9346868B2 (en) | 2011-11-14 | 2016-05-24 | Carlos Witte-Hoffmann | BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013116829A1 (en) | 2012-02-03 | 2013-08-08 | The Trustees Of Princeton University | Novel engineered potent cytotoxic stapled bh3 peptides |
| KR102112373B1 (ko) * | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| US9556229B2 (en) | 2012-05-18 | 2017-01-31 | The Regents Of The University Of California | Modification of peptides using a bis(thioether)arylbridge approach |
| CA3113959A1 (en) | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| WO2014053881A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| KR101616603B1 (ko) | 2012-10-11 | 2016-04-28 | 서울대학교산학협력단 | 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법 |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| CA2894202A1 (en) | 2012-12-18 | 2014-06-26 | The Secretary Of State For Health | Antimicrobial compounds, their synthesis and applications thereof |
| US9493510B2 (en) | 2013-01-10 | 2016-11-15 | Noliva Therapeutics Llc | Peptidomimetic compounds |
| US9115184B2 (en) | 2013-03-01 | 2015-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Light-inducible system for regulating protein stability |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US10017551B2 (en) | 2013-03-15 | 2018-07-10 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
| US20160244494A1 (en) | 2013-10-01 | 2016-08-25 | President And Fellows Of Harvard College | Stabilized polypeptides and uses thereof |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10682388B2 (en) | 2014-01-15 | 2020-06-16 | The Board Of Regents Of The University Of Texas System | Targeting of PELP1 in cancer therapy |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| WO2015175642A2 (en) | 2014-05-13 | 2015-11-19 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
| CN114805527A (zh) | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
| US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
| JP2017538427A (ja) | 2014-12-18 | 2017-12-28 | インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド | Crispr系組成物及び使用方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2016211517B2 (en) | 2015-01-28 | 2021-05-13 | Caribou Biosciences, Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US10464975B2 (en) | 2015-07-02 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20190002506A1 (en) * | 2015-08-28 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| JP7049989B2 (ja) * | 2015-08-28 | 2022-04-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Bfl-1と結合するペプチド |
| CN109069578A (zh) | 2016-02-29 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | 用于治疗感染的钉合的细胞内靶向抗微生物肽 |
| US20190076504A1 (en) | 2016-03-23 | 2019-03-14 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS |
| CN120118207A (zh) * | 2017-12-15 | 2025-06-10 | 丹娜-法伯癌症研究院有限公司 | 稳定肽-介导的靶向蛋白降解 |
-
2018
- 2018-12-14 CN CN202510303424.3A patent/CN120118207A/zh active Pending
- 2018-12-14 EP EP18839646.9A patent/EP3724216A1/en active Pending
- 2018-12-14 JP JP2020532803A patent/JP2021506814A/ja active Pending
- 2018-12-14 WO PCT/US2018/065784 patent/WO2019118893A1/en not_active Ceased
- 2018-12-14 US US16/766,083 patent/US20200354413A1/en not_active Abandoned
- 2018-12-14 CA CA3078682A patent/CA3078682A1/en active Pending
- 2018-12-14 AU AU2018385697A patent/AU2018385697B2/en active Active
- 2018-12-14 CN CN201880088640.9A patent/CN112119085B/zh active Active
-
2023
- 2023-02-23 US US18/113,539 patent/US20240140999A1/en active Pending
- 2023-06-13 JP JP2023096835A patent/JP2023107892A/ja active Pending
-
2024
- 2024-01-29 AU AU2024200512A patent/AU2024200512B2/en active Active
-
2025
- 2025-07-11 JP JP2025117357A patent/JP2025137626A/ja active Pending
-
2026
- 2026-03-10 AU AU2026201801A patent/AU2026201801A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017201449A1 (en) * | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| CELL CHEMICAL BIOLOGY REVIEW, vol. 24, JPN6022052972, 21 September 2017 (2017-09-21), pages 1181 - 1190, ISSN: 0005134967 * |
| RICHARDSON, STACIE L.: "Towards the developmentof a peptide-PROTAC conjugate targeting a viral protein: Rational design and", DIVISION OF MEDICINAL CHEMISTRY SCIENTIFIC ABSTRACTS FOR THE 254TH NATIONAL MEETING AND EXPOSITION, JPN6022052973, pages 96, ISSN: 0005134966 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025137626A (ja) * | 2017-12-15 | 2025-09-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化ペプチドによって介在される標的タンパク質の分解 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023107892A (ja) | 2023-08-03 |
| AU2026201801A1 (en) | 2026-04-02 |
| JP2025137626A (ja) | 2025-09-19 |
| CA3078682A1 (en) | 2019-06-20 |
| WO2019118893A1 (en) | 2019-06-20 |
| EP3724216A1 (en) | 2020-10-21 |
| AU2024200512A1 (en) | 2024-02-15 |
| US20200354413A1 (en) | 2020-11-12 |
| US20240140999A1 (en) | 2024-05-02 |
| AU2018385697A1 (en) | 2020-04-30 |
| CN112119085B (zh) | 2025-04-01 |
| AU2018385697B2 (en) | 2023-11-09 |
| AU2024200512B2 (en) | 2026-01-08 |
| CN112119085A (zh) | 2020-12-22 |
| CN120118207A (zh) | 2025-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024200512B2 (en) | Stabilized peptide-mediated targeted protein degradation | |
| US12570698B2 (en) | Stabilized peptides for covalent binding to target protein | |
| JP7394903B2 (ja) | Bfl-1と結合するペプチド | |
| US10308926B2 (en) | Stablized EZH2 peptides | |
| US12466853B2 (en) | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | |
| JP2023546561A (ja) | ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 | |
| HK40126659A (en) | Stabilized peptide-mediated targeted protein degradation | |
| KR20250162589A (ko) | 호흡기 세포융합 바이러스 표면 당단백질 펩티드, 접합체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230310 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230823 |